Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash & Equivalents (2020 - 2026)

Rani Therapeutics Holdings' Cash & Equivalents history spans 7 years, with the latest figure at $43.4 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 329.24% to $43.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $43.4 million, a 329.24% increase, with the full-year FY2025 number at $18.6 million, up 394.9% from a year prior.
  • Cash & Equivalents came in at $43.4 million for Q1 2026, up from $18.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $107.8 million in Q1 2022, with the low at $3.8 million in Q4 2024.
  • Historically, Cash & Equivalents has averaged $23.7 million across 5 years, with a median of $10.1 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: plummeted 92.23% in 2023 and later surged 394.9% in 2025.
  • Year by year, Cash & Equivalents stood at $27.0 million in 2022, then tumbled by 78.29% to $5.9 million in 2023, then crashed by 35.85% to $3.8 million in 2024, then surged by 394.9% to $18.6 million in 2025, then surged by 133.11% to $43.4 million in 2026.
  • Business Quant data shows Cash & Equivalents for RANI at $43.4 million in Q1 2026, $18.6 million in Q4 2025, and $4.1 million in Q3 2025.